Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Xinan Sheng

Showing results (31-40 of 133) with videos related to

Pageof 14
Sort By:
NPJ Genomic Medicine|February 5, 2021
Ratio of the interferon-γ signature to the immunosuppression signature predicts anti-PD-1 therapy response in melanomaChuanliang Cui, Canqiang Xu, Wenxian Yang, et al.
Cell Death & Disease|March 16, 2019
RBCK1 promotes p53 degradation via ubiquitination in renal cell carcinomaSifan Yu, Jie Dai, Meng Ma, et al.
Cancer Metastasis Reviews|July 2, 2026
HER2 assessment in urothelial carcinoma: standardization challenges and the path forwardPeipei Xie, Yajie Wang, Lei Lu, et al.
Cancer Investigation|May 23, 2025
Clinical Characteristics and Impact on Prognosis of Melanoma Accompanied by Multiple Primary Malignancies: A Retrospective AnalysisHuichun Tian, Jiaran Zhang, Lili Mao, et al.
European Journal of Cancer (Oxford, England : 1990)|July 21, 2019
Identification of a functional polymorphism within the 3'-untranslated region of denticleless E3 ubiquitin protein ligase homolog associated with survival in acral melanomaLu Yang, Jie Dai, Meng Ma, et al.
BMC Cancer|March 16, 2020
Pazopanib versus sunitinib in Chinese patients with locally advanced or metastatic renal cell carcinoma: pooled subgroup analysis from the randomized, COMPARZ studiesXinan Sheng, Jie Jin, Zhisong He, et al.
The British Journal of Ophthalmology|January 18, 2015
Prognostic factors for conjunctival melanoma: a study in ethnic Chinese patientsXinan Sheng, Siming Li, Zhihong Chi, et al.
BMC Medicine|July 2, 2026
Evaluation and analysis of renal injury in patients with advanced renal cell carcinoma receiving first-line benmelstobart plus anlotinib: results from the ETER100 studyJuan Li, Huichun Tian, Huayan Xu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 18, 2013
Large-scale analysis of PDGFRA mutations in melanomas and evaluation of their sensitivity to tyrosine kinase inhibitors imatinib and crenolanibJie Dai, Yan Kong, Lu Si, et al.
World Journal of Urology|April 2, 2025
A prognostic model for survival of patients with metastatic upper tract urothelial carcinoma with first-line systemic therapySiming Li, Jinchang Wei, Huayan Xu, et al.
Pageof 14

Showing results (31-40 of 133) with videos related to

Sort By:
Pageof 14
NPJ Genomic Medicine|February 5, 2021
Ratio of the interferon-γ signature to the immunosuppression signature predicts anti-PD-1 therapy response in melanomaChuanliang Cui, Canqiang Xu, Wenxian Yang, et al.
Cell Death & Disease|March 16, 2019
RBCK1 promotes p53 degradation via ubiquitination in renal cell carcinomaSifan Yu, Jie Dai, Meng Ma, et al.
Cancer Metastasis Reviews|July 2, 2026
HER2 assessment in urothelial carcinoma: standardization challenges and the path forwardPeipei Xie, Yajie Wang, Lei Lu, et al.
Cancer Investigation|May 23, 2025
Clinical Characteristics and Impact on Prognosis of Melanoma Accompanied by Multiple Primary Malignancies: A Retrospective AnalysisHuichun Tian, Jiaran Zhang, Lili Mao, et al.
European Journal of Cancer (Oxford, England : 1990)|July 21, 2019
Identification of a functional polymorphism within the 3'-untranslated region of denticleless E3 ubiquitin protein ligase homolog associated with survival in acral melanomaLu Yang, Jie Dai, Meng Ma, et al.
BMC Cancer|March 16, 2020
Pazopanib versus sunitinib in Chinese patients with locally advanced or metastatic renal cell carcinoma: pooled subgroup analysis from the randomized, COMPARZ studiesXinan Sheng, Jie Jin, Zhisong He, et al.
The British Journal of Ophthalmology|January 18, 2015
Prognostic factors for conjunctival melanoma: a study in ethnic Chinese patientsXinan Sheng, Siming Li, Zhihong Chi, et al.
BMC Medicine|July 2, 2026
Evaluation and analysis of renal injury in patients with advanced renal cell carcinoma receiving first-line benmelstobart plus anlotinib: results from the ETER100 studyJuan Li, Huichun Tian, Huayan Xu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 18, 2013
Large-scale analysis of PDGFRA mutations in melanomas and evaluation of their sensitivity to tyrosine kinase inhibitors imatinib and crenolanibJie Dai, Yan Kong, Lu Si, et al.
World Journal of Urology|April 2, 2025
A prognostic model for survival of patients with metastatic upper tract urothelial carcinoma with first-line systemic therapySiming Li, Jinchang Wei, Huayan Xu, et al.
Pageof 14